Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $44.83.
Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $59.00 price target on shares of Belite Bio in a research report on Thursday, June 13th. Benchmark reaffirmed a “buy” rating and issued a $57.00 target price on shares of Belite Bio in a research report on Thursday, May 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Belite Bio in a report on Thursday, June 20th.
Check Out Our Latest Research Report on BLTE
Institutional Trading of Belite Bio
Belite Bio Trading Up 3.5 %
Belite Bio stock opened at $50.33 on Tuesday. The stock has a fifty day moving average price of $47.41 and a 200 day moving average price of $44.48. Belite Bio has a 52 week low of $15.00 and a 52 week high of $50.66. The firm has a market capitalization of $1.50 billion, a P/E ratio of -42.65 and a beta of -1.47.
Belite Bio (NASDAQ:BLTE – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. As a group, equities analysts predict that Belite Bio will post -1.08 EPS for the current year.
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
- Five stocks we like better than Belite Bio
- How to Effectively Use the MarketBeat Ratings Screener
- Why This AI Stock is Rising Despite Tech Sell-Off
- What Are the U.K. Market Holidays? How to Invest and Trade
- MarketBeat Week in Review – 7/15 – 7/19
- The How and Why of Investing in Gold Stocks
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.